Recent Press Releases

Global Transdermal Drug Delivery Market 2014-2018

LONDON, July 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Global Transdermal Drug Delivery Market 2014-2018...

EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology

SALT LAKE CITY and TORONTO, July 29, 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of...

Phosphagenics Provides Update on Opioid Patch Program

MELBOURNE, Australia, July 29, 2014 /PRNewswire/ -- Next phase of the TPM®/Oxymorphone clinical development program has commenced TPM®/Oxycodone Phase 2a trial to be conducted in Australia...

Oraya Therapeutics Announces Rapid Expansion in Europe as More Hospitals Offer Oraya Therapy for Treating Wet AMD

First National Health Service hospital in UK and four prestigious hospitals in Germany adopt Oraya Therapy to maintain vision with reduced anti-VEGF injections NEWARK, Calif., July 22,...

Scientists test a Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer

Released: 25-Jul-2014 9:30 AM EDT Source Newsroom: Norris Cotton Cancer CenterDartmouth-Hitchcock Medical Center more news from this source Contact Information Available for logged-in reporters only...

AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso™

AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso™ REDWOOD CITY, Calif., July 25, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq:...

Supermaterial gives rejected drugs a new chance

22 July 2014 Uppsala Universitet More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now...

Innocutis Introduces Sitavig® 50mg (ACYCLOVIR) Muco-Adhesive Buccal Tablet For Relief From Herpes Labialis (Cold Sores)

CHARLESTON, S.C., July 21, 2014 /PRNewswire/ -- Innocutis is pleased to announce the introduction into the North American markets of Sitavig® (ACYCLOVIR) 50mg Buccal Tablet. Sitavig®...

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics

– Allowed Claims of Manoharan '478 Application Cover GalNAc-Conjugates Independent of Length, Sequence, and Disease Target – July 22, 2014 08:00 AM Eastern Daylight Time...

Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence

Study Completion Expected in Mid-2015 Followed by Potential Resubmission of Probuphine New Drug Application SOUTH SAN FRANCISCO, CA, Jul 21, 2014 (Marketwired via COMTEX) -- TitanPharmaceuticals,...

Galena Biopharma Enters into Definitive Agreement to License U.S. Rights for Zuplenz® (ondansetron) Oral Soluble Film

· Novel, rapidly dissolving oral PharmFilm® enables faster absorption, increased convenience and better compliance for patients. · Planned launch in multiple...

MicroCHIPS, Inc. appoints Cheryl R. Blanchard, Ph.D., as Chief Executive Officer

MicroCHIPS, Inc. appoints Cheryl R. Blanchard, Ph.D., as Chief Executive Officer Industry veteran to lead next stage of commercialization for implantable drug delivery devices, with near-term focus...

Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United States

TORONTO, CANADA – Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company focused on Parkinson's disease, today announced that following communication...

Zogenix Announces New Patent Valid Through 2032 For DosePro(R) Needle-Free Delivery System

SAN DIEGO, July 14, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the issuance of a new patent, US 8,734,384, from the United States Patent and Trademark Office (USPTO). The...

FDA Designates Opioid Overdose Treatment for Fast Track Development Program

FDA Designates Opioid Overdose Treatment for Fast Track Development Program Milestone accelerates AntiOp's path toward approval and commercialization LEXINGTON, Ky., Jul 15, 2014 (BUSINESS WIRE)...

Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates

Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates SAN DIEGO,...

Covidien Launches Next-Generation Trellis™ Peripheral Infusion System

Treatment for Deep Vein Thrombosis Redesigned to Improve Thrombus Isolation, Lytic Drug Delivery, Removal of Blood Clot July 08, 2014 07:30 AM Eastern Daylight Time BOSTON--(BUSINESS WIRE)--Covidien...

InSite Vision Plans to Submit New Drug Application to FDA for DexaSite™ for the Treatment of Blepharitis in Adults

DexaSite NDA Submission Planned for 2015; AzaSite Plus™ Data and Endpoint Discussions with FDA Continue European post-Phase 3/pre-MAA DexaSite and AzaSite Plus Blepharitis Discussions Scheduled...

Icon Bioscience Announces Early Completion of Patient Enrollment in Its Phase 3 Study of IBI-10090; Drug Addresses Market Need for Long-Acting Treatment of Inflammation Post Cataract Surgery

SUNNYVALE, Calif.--(BUSINESS WIRE)--Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care...

Alnylam Elects Amy Schulman to its Board of Directors

– Appointment of Industry Leader Brings Broad Strategic, Commercial, and Legal Experience to Board – July 02, 2014 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS...